Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (VKTX) is a clinical-stage biopharmaceutical company pioneering receptor-targeted therapies for metabolic and endocrine disorders. This page serves as the definitive source for all official updates and analysis-worthy developments related to the company’s innovative pipeline.
Investors and industry observers will find timely, verified information spanning clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes press releases on key programs like the thyroid receptor agonist VK2809 for NASH, dual GLP-1/GIP agonist VK2735 for obesity, and rare disease candidate VK0214 – all developed through Viking’s receptor-specific therapeutic approach.
Content is organized to highlight material events including Phase 1-3 trial results, FDA communications, patent developments, and peer-reviewed research publications. Each update is contextualized within Viking’s broader mission to address unmet needs in metabolic health through precision pharmacology.
For consistent monitoring of Viking’s advancements in liver disease and endocrine disorder treatments, bookmark this page and revisit for authoritative reporting on trial data disclosures and corporate announcements. All content adheres to strict journalistic standards for accuracy and regulatory compliance.
Viking Therapeutics (NASDAQ: VKTX) has announced its participation in three upcoming investor conferences. The first is the HC Wainwright Global Life Science Conference on March 9-10, 2021, where a corporate presentation will be available online. This is followed by the 33rd Annual Roth Conference on March 15-17 and the Oppenheimer's 31st Annual Healthcare Conference on March 16-18, with presentations and meetings scheduled. The company focuses on therapies for metabolic disorders, including its drugs VK2809 and VK0214, currently in clinical trials.
Viking Therapeutics (NASDAQ: VKTX) reported its fourth quarter and full-year 2020 financial results, revealing a net loss of $10.9 million for Q4, up from $7.5 million in Q4 2019. The total net loss for 2020 was $39.5 million, compared to $25.8 million in 2019. R&D expenses surged to $31.9 million, driven by clinical trial costs. The company maintains a strong balance sheet with $248.4 million in cash. Viking's ongoing VOYAGE trial for VK2809 and progress in the VK0214 program highlight its focus on metabolic disorders.
Viking Therapeutics (NASDAQ: VKTX) will report its financial results for Q4 and year-end 2020 after market close on February 17, 2021. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss the results and corporate updates. Investors can participate by dialing (844) 850-0543 or (412) 317-5199, and a telephone replay will be available until February 24, 2021. Viking is focused on metabolic and endocrine disorder therapies, with ongoing clinical programs for VK2809 and VK0214.
On January 6, 2021, Viking Therapeutics (NASDAQ: VKTX) announced the promotion of Greg Zante to Chief Financial Officer and Marianne Mancini to Chief Operating Officer. Zante brings nearly 25 years of experience in financial management and previously served as Senior Vice President of Finance at Viking. Mancini has over 30 years of experience, focusing on clinical trials, and was previously Senior Vice President of Clinical Operations. These promotions reflect their significant contributions to the company, particularly in advancing therapies for metabolic disorders including non-alcoholic steatohepatitis (NASH).
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced its CEO, Brian Lian, Ph.D., will present at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The presentation will be available online starting on January 11. Viking Therapeutics specializes in developing innovative therapies for metabolic and endocrine disorders. Key programs include VK2809, targeting non-alcoholic steatohepatitis (NASH) and fibrosis, and VK0214, aimed at X-linked adrenoleukodystrophy (X-ALD), indicating strong potential in the biopharmaceutical landscape.
Viking Therapeutics (NASDAQ: VKTX) is set to present at the Stifel Healthcare Conference 2020, with CEO Brian Lian, Ph.D., delivering insights on the company's innovative therapies for metabolic and endocrine disorders. The virtual event will occur from November 16-18, 2020, with Viking's presentation scheduled for 11:40 a.m. PST on November 17, 2020. Investors can access the live webcast on Viking's website, where a replay will also be available post-conference. Viking is advancing its clinical programs, which include VK2809 and VK0214, targeting significant health issues.
Viking Therapeutics (NASDAQ: VKTX) reported its Q3 financial results with a net loss of $9.3 million, or $0.13 per share, compared to a loss of $5.7 million last year. Key developments include ongoing enrollment in the Phase 2b VOYAGE study for VK2809 targeting non-alcoholic steatohepatitis (NASH) and the initiation of a Phase 1 trial for VK0214, aimed at treating X-linked adrenoleukodystrophy (X-ALD). The company ended the quarter with approximately $255 million in cash, supporting further clinical advancements despite challenges posed by the COVID-19 pandemic.
Viking Therapeutics (NASDAQ: VKTX) will announce its third quarter 2020 financial results on October 28, 2020. The announcement follows an upcoming conference call scheduled for 4:30 p.m. ET that same day to discuss the results and corporate updates. Interested parties can join via phone or by visiting the company's website for a live webcast. Viking is known for developing innovative therapies for metabolic and endocrine disorders, including VK2809 for treating non-alcoholic steatohepatitis (NASH) and VK0214 for X-linked adrenoleukodystrophy (X-ALD).
Viking Therapeutics (NASDAQ: VKTX) has initiated a Phase 1 clinical trial for VK0214, an orally available thyroid receptor beta agonist aimed at treating X-linked adrenoleukodystrophy (X-ALD). Following FDA clearance of its IND application, the trial will assess the safety, tolerability, and pharmacokinetics of VK0214 in healthy subjects. Preclinical findings indicate that VK0214 may significantly reduce very long chain fatty acids (VLCFAs), which are implicated in X-ALD. The company aims to begin a Phase 1b study in X-ALD patients upon successful completion of the initial trial.
Viking Therapeutics (NASDAQ: VKTX) announced participation in four investor conferences in September 2020. The events include the Citi's 15th Annual BioPharma Conference on September 9-10, Morgan Stanley Global Healthcare Conference on September 14-16, Cantor Fitzgerald Virtual Global Healthcare Conference from September 15-17, and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21-23. The Cantor Fitzgerald and Oppenheimer presentations will be available via webcast on the company's website. Viking is focused on developing therapies for metabolic and endocrine disorders.
FAQ
What is the current stock price of Viking Therapeutics (VKTX)?
What is the market cap of Viking Therapeutics (VKTX)?
